Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

BACKGROUND AND PURPOSE: Analogues of fibroblast growth factor 21 (FGF21) demonstrate diverse metabolic benefits in preclinical models of type 2 diabetes, dyslipidaemia and non‐alcoholic steatohepatitis (NASH), but clinical responses with different analogues are inconsistent. Efruxifermin is an Fc‐FG...

Descripción completa

Detalles Bibliográficos
Autores principales: Tillman, Erik J., Brock, William J., Rolph, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306736/
https://www.ncbi.nlm.nih.gov/pubmed/34773249
http://dx.doi.org/10.1111/bph.15725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306736/
https://www.ncbi.nlm.nih.gov/pubmed/34773249
http://dx.doi.org/10.1111/bph.15725

Ejemplares similares